195 related articles for article (PubMed ID: 26038704)
1. A comparison of linaclotide and lubiprostone dosing regimens on ion transport responses in human colonic mucosa.
Kang SB; Marchelletta RR; Penrose H; Docherty MJ; McCole DF
Pharmacol Res Perspect; 2015 Mar; 3(2):e00128. PubMed ID: 26038704
[TBL] [Abstract][Full Text] [Related]
2. The ClC-2 Chloride Channel Activator, Lubiprostone, Improves Intestinal Barrier Function in Biopsies from Crohn's Disease but Not Ulcerative Colitis Patients.
Park YS; Kang SB; Marchelletta RR; Penrose HM; Ruiter-Visser R; Jung B; Docherty MJ; Boland BS; Sandborn WJ; McCole DF
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986672
[TBL] [Abstract][Full Text] [Related]
3. Contrasting effects of linaclotide and lubiprostone on restitution of epithelial cell barrier properties and cellular homeostasis after exposure to cell stressors.
Cuppoletti J; Blikslager AT; Chakrabarti J; Nighot PK; Malinowska DH
BMC Pharmacol; 2012 May; 12():3. PubMed ID: 22553939
[TBL] [Abstract][Full Text] [Related]
4. Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone.
Moeser AJ; Nighot PK; Engelke KJ; Ueno R; Blikslager AT
Am J Physiol Gastrointest Liver Physiol; 2007 Feb; 292(2):G647-56. PubMed ID: 17053162
[TBL] [Abstract][Full Text] [Related]
5. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
[TBL] [Abstract][Full Text] [Related]
6. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
[TBL] [Abstract][Full Text] [Related]
7. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate.
Castro J; Harrington AM; Hughes PA; Martin CM; Ge P; Shea CM; Jin H; Jacobson S; Hannig G; Mann E; Cohen MB; MacDougall JE; Lavins BJ; Kurtz CB; Silos-Santiago I; Johnston JM; Currie MG; Blackshaw LA; Brierley SM
Gastroenterology; 2013 Dec; 145(6):1334-46.e1-11. PubMed ID: 23958540
[TBL] [Abstract][Full Text] [Related]
8. Evaluating When and Why Patients Discontinue Chronic Therapy for Irritable Bowel Syndrome With Constipation and Chronic Idiopathic Constipation.
Shah ED; Suresh S; Jou J; Chey WD; Stidham RW
Am J Gastroenterol; 2020 Apr; 115(4):596-602. PubMed ID: 32022721
[TBL] [Abstract][Full Text] [Related]
9. Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States.
Nag A; Bornheimer R; Oster G
Drugs Context; 2020; 9():. PubMed ID: 32863841
[TBL] [Abstract][Full Text] [Related]
10. Lubiprostone: RU 0211, SPI 0211.
Drugs R D; 2005; 6(4):245-8. PubMed ID: 15991886
[TBL] [Abstract][Full Text] [Related]
11. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome.
Andresen V; Camilleri M; Busciglio IA; Grudell A; Burton D; McKinzie S; Foxx-Orenstein A; Kurtz CB; Sharma V; Johnston JM; Currie MG; Zinsmeister AR
Gastroenterology; 2007 Sep; 133(3):761-8. PubMed ID: 17854590
[TBL] [Abstract][Full Text] [Related]
12. Linaclotide inhibits colonic and urinary bladder hypersensitivity in adult female rats following unpredictable neonatal stress.
Ligon C; Mohammadi E; Ge P; Hannig G; Higgins C; Greenwood-Van Meerveld B
Neurogastroenterol Motil; 2018 Oct; 30(10):e13375. PubMed ID: 29797376
[TBL] [Abstract][Full Text] [Related]
13. Linaclotide: a novel compound for the treatment of irritable bowel syndrome with constipation.
Rothstein RD; Friedenberg FK
Expert Opin Pharmacother; 2013 Oct; 14(15):2125-32. PubMed ID: 24007408
[TBL] [Abstract][Full Text] [Related]
14. Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transit.
Busby RW; Bryant AP; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Mahajan-Miklos S; Pierce CM; Solinga RM; Sun LJ; Tobin JV; Kurtz CB; Currie MG
Eur J Pharmacol; 2010 Dec; 649(1-3):328-35. PubMed ID: 20863829
[TBL] [Abstract][Full Text] [Related]
15. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.
Busby RW; Kessler MM; Bartolini WP; Bryant AP; Hannig G; Higgins CS; Solinga RM; Tobin JV; Wakefield JD; Kurtz CB; Currie MG
J Pharmacol Exp Ther; 2013 Jan; 344(1):196-206. PubMed ID: 23090647
[TBL] [Abstract][Full Text] [Related]
17. Lubiprostone reverses the inhibitory action of morphine on intestinal secretion in guinea pig and mouse.
Fei G; Raehal K; Liu S; Qu MH; Sun X; Wang GD; Wang XY; Xia Y; Schmid CL; Bohn LM; Wood JD
J Pharmacol Exp Ther; 2010 Jul; 334(1):333-40. PubMed ID: 20406855
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the chloride channel activator lubiprostone and the oral laxative Polyethylene Glycol 3350 on mucosal barrier repair in ischemic-injured porcine intestine.
Moeser AJ; Nighot PK; Roerig B; Ueno R; Blikslager AT
World J Gastroenterol; 2008 Oct; 14(39):6012-7. PubMed ID: 18932279
[TBL] [Abstract][Full Text] [Related]
19. Current and emerging treatments for irritable bowel syndrome with constipation and chronic idiopathic constipation: focus on prosecretory agents.
Thomas RH; Luthin DR
Pharmacotherapy; 2015 Jun; 35(6):613-30. PubMed ID: 26016701
[TBL] [Abstract][Full Text] [Related]
20. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator.
Bijvelds MJ; Bot AG; Escher JC; De Jonge HR
Gastroenterology; 2009 Sep; 137(3):976-85. PubMed ID: 19454284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
